• Wrong document? Swap it for free
  • Written by students who passed
  • Immediately available after payment
  • Read online or as PDF
Sell
Where do you study
Your language
Start selling Create your account
Document preview thumbnail
Preview 2 out of 5 pages
Exam (elaborations)

NR201.StudyGuide.Oncology Complete

Document preview thumbnail
Preview 2 out of 5 pages

NR201.StudyGuide.Oncology Complete

Content preview

NR 201- Fall
Oncology Study Guide

 Cancer types
o Carcinoma – Skin, Sarcoma – bone, Leukemia – Blood, Lymphoma/myeloma – immune,
CNS – brain/spinal
 Cell Division
o Hyperplasia -  # of cells
o Dysplasia – abnormal cells
o in Situ – abnormal cells ‘in place’, haven’t spread
 Modifiable and non-modifiable risk factors for cancer
o Modifiable- smoking, alcohol, obesity, diet, sun exposure
o Non-Modifiable- race, heredity, age
 Most common cancers in:
o Men - Prostate
o Women - Breast
o Children- Leukemia
o Highest mortality rate for men and women - Lung and bronchus
 Cancers with highest mortality rates – ones that there are screening guidelines for
o Lung, breast, prostate, colon, cervical, uterine
 Screening guidelines for breast, ovarian, colon and prostate cancer – Lecture #1 slides 60-65
o Immediate family member with cancer you should start screenings 10-15 yrs earlier
o Breast
 Over 30 with immediate family member screen now
 40-44 begin mammograms
 54 yearly mammograms
 55+ every 2 years or yearly
o Cervical
 21 begin screening
 21-29 PAP / 3yrs, HPV test only after abnormal PAP
 30-65 PAP+HPV / 5yrs or PAP /3yrs
 65+ with regular screening can stop
 Cancer hx should screen for +20 yrs
 Prevention: Gardasil – 2x 11-12yrs, 3x 15-26yrs
o Colorectal cancer screening
 45 begin screening, high risk start sooner
 76-85 screening based on preference and Hx
 85+ end screening
 Fecal immunochemical test (FIT) /1yr
 Guaiac-based fecal occult blood test (gFOBT) /1yr
 Stool DNA test/3yrs
 Digital rectal exam
 Colonoscopy / 10yrs
 Polyps + cancer - CT colonoscopy, flex sigmoidoscopy, contrast barium /5yrs
o Prostate cancer screening
 50 begin screening, 45 for AA with relative, 40 high risk and relative
 PSA blood test with or without a rectal exam, biopsy to confirm
 Staging cancer TNM
o The higher the number the more involvement
o T = Size and involvement of the local neoplasm

1
This study source was downloaded by 100000849044796 from CourseHero.com on 07-07-2022 03:45:52 GMT -05:00


https://www.coursehero.com/file/85856630/NR201StudyGuideOncology-Completedocx/

, NR 201- Fall
Oncology Study Guide

 T Subclass – T=Primary Tumor
 Tx - tumor cannot be assessed
 T0 - no evidence of primary tumor
 TIS - carcinoma in situ
 T1 - T4 – progressive increase in tumor size and involvement
o N= Regional Lymph node
 Nx-regional lymph nodes cannot be clinically assessed
 N0-regional lymph nodes demonstrably normal
 N1 - N4-Increasing degrees of abnormalities of regional lymph nodes
o M= Distant Metastasis
 Mx-not assessed
 M0-no (known) distant metastasis
 M1- M4 -distant metastasis present, specify site(s)
 Grading cancer
o The higher the number the more involvement
o Grade-classification of tumor cells based on cellular differentiation, or resemblance to
normal cells in structure, function, and maturity.
o Grade I - Well Differentiated: cancer cells that closely resemble the tissue of origin.
o Grade II - Moderately well differentiated; some immaturity present
o Grade III - Poorly differentiated; little resemblance to normal parent tissue
o Grade IV - Undifferentiated: bizarre tumor cells, no similarity to the tissue or origin.
o Grade X - unable to be assessed
 Means to diagnose cancer
o Tumor marker, MRI, CT, Fluoroscopy, U/S, Endo, Nuclear Imaging, PET Scan,
o Must confirm with biopsy
o Tumor markers
 PSA, BRCA1 and BRCA2,
 Common warning signs and symptoms of breast, lung, colon and prostate cancer
o C -change in bowel or bladder habits
o A- a sore that does not heal
o U- unusual bleeding or discharge
o T- thickening or lump in the breast tissue
o I- indigestion or difficulty swallowing
o O- obvious changes in wart or mole
o N- nagging cough or hoarseness
 Benign vs malignant
o Benign – encapsulated, noninvasive, well differentiated, slow grow, local, no anaplasia,
no metastases
o Malignant- invasive, poor differentiation, rapid grow, anaplasia, metastases
Treatment
 Hormonal therapy
o Change in environment where tumor grows
o Effective for hormone dependent tumors: breast, ovary, prostate, testicular
o Side effects: changes in wt, mood, skin, cardiac, BP, nausea, hirsutism, baldness. Hot
flashes, fluid retention, liver toxicity, gynecomastia
o Leuprolide – used as treatment for hormonal cancers


2
This study source was downloaded by 100000849044796 from CourseHero.com on 07-07-2022 03:45:52 GMT -05:00


https://www.coursehero.com/file/85856630/NR201StudyGuideOncology-Completedocx/

Document information

Uploaded on
July 7, 2022
Number of pages
5
Written in
2021/2022
Type
Exam (elaborations)
Contains
Questions & answers
£11.49

Wrong document? Swap it for free Within 14 days of purchase and before downloading, you can choose a different document. You can simply spend the amount again.
Written by students who passed
Immediately available after payment
Read online or as PDF

Sold
9
Followers
5
Items
234
Last sold
6 months ago



Why students choose Stuvia

Created by fellow students, verified by reviews

Quality you can trust: written by students who passed their exams and reviewed by others who've used these revision notes.

Didn't get what you expected? Choose another document

No problem! You can straightaway pick a different document that better suits what you're after.

Pay as you like, start learning straight away

No subscription, no commitments. Pay the way you're used to via credit card and download your PDF document instantly.

Student with book image

“Bought, downloaded, and smashed it. It really can be that simple.”

Alisha Student

Working on your references?

Create accurate citations in APA, MLA and Harvard with our free citation generator.

Working on your references?

Frequently asked questions